Last updated: 2026-10-09 22:23:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Revelation Biosciences, Inc. (REVB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.76, with a market capitalisation of $3.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.75 to $6.24. This page covers its latest market performance, valuation, price trends and company information.
$3.30M | |
$0.77 | |
$1,965,600.00 | |
$0.75 | |
$0.77 | |
24.75K | |
39.83K | |
-- | |
$6.24 | |
$0.75 | |
-- | |
-- |
Revelation Biosciences, Inc. (REVB) is trading at $0.76 in after-hours trading as of 2026-10-09 19:54:35, down 1.67% ($0.01) from the regular-session close of $0.77.
After-hours trading shows how investors are pricing REVB after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Revelation Biosciences, Inc. (REVB) moved from $0.82 to $0.76, representing a decline of 6.85% ($0.06).
The stock traded between $0.75 and $0.85 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 53.97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
REVB is currently trading at $0.76, placing it 0.2% of the way from its 52-week low of $0.75 to its 52-week high of $6.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Revelation Biosciences, Inc. (REVB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.